Mednet Logo
HomePediatric Hematology/Oncology
Pediatric Hematology/Oncology

Pediatric Hematology/Oncology

Clinical discussions on pediatric blood disorders, childhood cancers, and specialized treatment protocols.

Recent Discussions

What is the choice of treatment for a teenager with low risk neuroblastoma s/p resection?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Vanderbilt University Medical Center

According to the Revised Neuroblastoma Risk Classification (Irwin et al., PMID 34319759), age is not a factor in determining whether someone is low risk. So if this child has been determined to have low-risk neuroblastoma, they have/had an L1 tumor, either without MYCN amplification, or with MYCN am...

How do you integrate surgery in treatment of recurrent tenosynovial giant cell tumors (TGCT) when using Pexidartinib?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Dana-Farber Cancer Institute

This is an interesting question, but one that has little (if any) data to guide management. With recurrent TGCT, the patient presumably already had surgery. It is possible that a good response to pexidartinib may reduce the morbidity of a repeat surgery but the risk of additional recurrence would re...

Which chemo regimen, if any, would you use as adjuvant treatment in a young patient with primary malignant thyroid teratoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Testicular Cancer Commons

There is no evidence base to guide you here. The term "malignant teratoma" is not particularly helpful here and does not distinguish between benign teratoma, somatic transformation, or active germ cell malignancies. If classic markers AFP and HCG are significantly elevated, that would favor a malign...

What is the treatment of choice for mixed phenotype ALL?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · The University of Texas MD Anderson Cancer Center

These are difficult to treat. The limited available data suggest that an ALL–like regimen followed by HSCT may be recommended. If no response is achieved, you could try a myeloid-like strategy. For T/Myeloid, combining asparaginase with AML therapy (FA + PEG or Capizzi II) could be an option. The sp...

Do you stop hydroxyurea or switch to an alternative therapy in a male patient with controlled Hb SC disease who is interested in having children?

2 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Nationwide Children's Hospital

Part of the reason the patient may have controlled disease could be the hydroxyurea and so stopping that therapy might not be best for the patient's disease. Also, many patients on hydroxyurea can still get their partner pregnant. So, I would only consider stopping/holding it if the patient is havin...

What is your approach to BK hemorrhagic cystitis not responding to cidofovir?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Loma Linda University Health

BK hemorrhagic cystitis can range from completely asymptomatic infection (with positive BK viremia and viruria by PCR) or grade 0 to massive macroscopic hematuria requiring instrumentation for clot evacuation and urinary obstruction requiring bilateral nephrostomy tubes for urine diversion (grade 4)...

Which patients with acute promyelocytic leukemia do you consider maintenance after completing consolidation?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Northwestern University

Before we address the role of maintenance in APL, several principles are important to note. First, APL is now a highly curable disease with contemporary therapeutic strategies. Second, we now divide patients into low-risk and high-risk based solely on the presenting WBC (< or =10,000/uL vs >10,000/u...

How do you advise patients with sickle cell disease on contraception?

1 Answers

Mednet Member
Mednet Member
Hematology · Dana-Farber Cancer Institute

According to both the "ASH Pocket Guidelines" and the National Heart Lung and Blood Guidelines for health maintenance in Women with sickle cell disease, progestin only and barrier methods of contraception are the preferred recommendations for contraception. Combined hormonal agents can be considered...

How do you approach the management of GVHD prophylaxis in the setting of severe infection?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

GVHD prophylaxis the 1st ~ 3 months after alloSCT is paramount and immunosuppression withdrawal might cause GVHD which can in turn exacerbate or cause infection given the need of corticosteroids to control it. Having said that, case-by-case management is important. As an example, alloSCT using a PTC...

How would you approach management of bleeding risk and factor VIII replacement in a patient with severe hemophilia A undergoing stem cell transplant?

1 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Georgetown University Hospital

Same way as anyone with severe hemophilia: Prophy with QOD factor or weekly hemlibra Extra correction for procedures, trauma, or bleeding